Cargando…
Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
Objectives: Inclusion of patient preference (PP) data in decision making has been largely discussed in recent years. Healthcare decision makers—regulatory and health technology assessment (HTA)—are more and more conscious of the need for a patient-centered approach to decide on optimal allocation of...
Autores principales: | Chachoua, Lylia, Dabbous, Monique, François, Clément, Dussart, Claude, Aballéa, Samuel, Toumi, Mondher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649266/ https://www.ncbi.nlm.nih.gov/pubmed/33195294 http://dx.doi.org/10.3389/fmed.2020.543046 |
Ejemplares similares
-
President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First
por: Dabbous, Monique, et al.
Publicado: (2019) -
Why “American Patients First” is likely to raise drug prices outside of the United States
por: Dabbous, Monique, et al.
Publicado: (2019) -
Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies
por: Dabbous, Omar, et al.
Publicado: (2022) -
Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015) -
Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
por: Dahmani, Hajer, et al.
Publicado: (2023)